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INTRODUCTION
Image-guided core needle biopsy (CNB) is considered the 
gold standard diagnostic modality for breast lesions and a 
reliable alternative to surgical excisional biopsy (1-5). Many 
studies have reported that percutaneous ultrasonography 
(US)-guided CNB has several advantages over stereotactic 
or surgical biopsy. It is less invasive, less expensive, and 
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faster to perform; further, it can be performed in real time 
while still allowing accurate assessments without exposure 
to ionizing radiation (4, 6, 7). Many studies also have 
proven that US-guided 14-gauge CNB provides optimal 
diagnostic information for breast lesions with low false-
negative rates and accuracy comparable to that of surgical 
biopsy (3, 5, 6, 8). Furthermore, the number of breast 
imaging studies utilizing screening mammography and US 
has increased, resulting in increased lesion detection and 
biopsy recommendation. Therefore, US-guided CNB has been 
increasingly performed since its introduction. However, 
its subsequent utilization has led to concerns about an 
unnecessary increase in the number of biopsies associated 
with benign biopsy results. 
In the United States, more than 1 million breast biopsies 
are performed annually, and approximately 80% of cases 
are benign (9, 10). However, data are limited on which 
lesions have been increasingly biopsied over time. US-
guided CNB would be cost-ineffective and would be of 
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hand technique and a high-resolution US unit with 5–15-
MHz linear transducers (HDI 5000 or 3000 or iU22, Philips’ 
Advanced Technology Laboratories, Bothell, WA, USA; 
or LOGIQ 9 or LOGIQ E9, GE Healthcare, Milwaukee, WI, 
USA). Each procedure was performed with the patient in 
the supine position under local anesthesia. A 14-gauge 
automated core biopsy needle with a spring-loaded biopsy 
gun (Promac 2.2 L, Manan Medical Products, Northbrook, IL, 
USA), a 14-gauge Tru-Cut needle with a 22-mm throw (SACN 
biopsy needle; Medical Device Technologies, Gainesville, FL, 
USA), or a 14-gauge dual-action semiautomatic core biopsy 
needle with a 22-mm throw (Stericut with a coaxial needle, 
TSK Laboratory, Tochigi, Japan) was used. All biopsies were 
performed by one of 42 radiologists with less than 2 years 
of experience who was in fellowship training, or by one of 
six radiologists with 2 or more years of clinical experience 
who was a specialist in breast imaging and biopsies. At 
least four or five core samples per lesion were routinely 
obtained. 
Data Analysis
The radiological and pathologic findings of US-guided 
14-gauge CNB were obtained from medical records. Breast 
lesions were classified based on the lesion size, BI-RADS 
category on US, and pathologic results of CNB. Each 
variable was categorized as follows: lesion size as ≤ 10 mm, 
>10 to ≤ 20 mm, >20 to ≤ 30 mm, >30 to ≤ 40 mm, or > 40 
mm; BI-RADS category on US (category 1 to 5); pathologic 
results of CNB as benign (neither malignant nor high-risk), 
high-risk (e.g., atypia, including atypical ductal hyperplasia, 
lobular neoplasia, radial sclerosing lesions, and possible 
phyllodes tumors), or malignant (e.g., ductal carcinoma in 
situ [DCIS] and invasive cancer). The malignancy rates for 
DCIS and invasive cancer were calculated as proportions 
clinical insignificance if the increasing number of biopsies 
does not lead to increased breast cancer detection. With 
the number of total biopsies increasing over time, the 
malignancy rate in the results of CNB must be kept constant 
or increase in order to ensure that unnecessary biopsies are 
not performed.
The purpose of this study was to examine annual trends 
in breast lesion characteristics (e.g., lesion size, the Breast 
Imaging-Reporting and Data System [BI-RADS] category 
established by the American College of Radiology, and 
pathologic findings) and the malignancy rate based on a 
large series of US-guided CNB over a 12-year study period.
MATERIALS AND METHODS
Study Population
This study was conducted with the approval of the 
Institutional Review Board (4-2019-0636), and the 
requirement for informed consent was waived.
 From January 2005 to December 2016, 22667 
consecutive US-guided 14-gauge CNBs for breast lesions 
from 211986 breast US procedures were performed at our 
institution. We retrospectively reviewed the biopsy results 
to analyze the annual trends in US-guided CNB. Proven 
malignancies assessed as BI-RADS category 6 lesions (n 
= 282), male patients (n = 62), and lesions with non-
diagnostic pathologic results (e.g., adipose tissue only or 
cell paucity) (n = 26) were excluded from this study. Finally, 
a total of 22297 breast masses of 17241 patients (mean 
age, 45.7 ± 11.6 years; range, 11 to 92 years) were included 
in this study.
Biopsy Procedure
US-guided 14-gauge CNB was performed using the free-
Table 1. Distribution of US-Guided 14-Gauge Core-Needle Biopsy and Total US, 2005–2016
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total
OR 
(95% CI)
P
No. of total  
   breast US 
examinations
7808 10635 11963 13766 17171 17859 19151 20808 21854 22377 22698 25896 211986
1.091
(1.089, 
1.093)
< 0.001
No. of US-guided  
   core-needle 
biopsies
1294 1504 1377 1639 1975 2080 1938 2019 1972 2111 2334 2054 22297
1.043
(1.039, 
1.047)
< 0.001
Percentage  
  (%)*
16.6 14.1 11.5 12.3 11.5 11.7 10.1 9.7 9.0 9.4 10.3 7.9
0.952
(0.948,
 0.956)
< 0.001
*Percentage of total core-needle biopsies performed among total USs. CI = confidence interval, OR = odds ratio, US = ultrasonography
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among all biopsied breast masses of DCIS and invasive 
cancer, respectively, diagnosed using US-guided 14-gauge 
CNB. The total malignancy rate was calculated as the total 
proportion of both DCIS and invasive cancer among all 
biopsied cases.
To assess overall trends over time in CNB based on the 
lesion size, BI-RADS category, and pathologic results, the 
Mantel-Haenszel chi-square test and Poisson regression 
analysis were performed. The Cochran-Armitage test was 
performed for trends in the malignancy rate and the 
Cochran-Mantel-Haenszel test was performed to adjust 
variables. A generalized linear model with an identity link 
for normal distribution was used to calculate the odds ratio 
(OR) for associations between the calendar year and each 
variable. OR was interpreted as the number of times each 
indicator increased each year. Analyses were performed 
with a computerized statistic program (SAS, version 9.4, 
Cary, NC, USA or SPSS, version 23.0, IBM Corp., Armonk, 
Table 2. Distribution of US-Guided 14-Gauge Core-Needle Biopsy According to Lesion Size and BI-RADS Category
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total
OR
(95% CI)
P
Size (mm)
≤ 10
575 
(44.4)
698 
(46.4)
682 
(49.5)
959 
(58.5)
989 
(50.1)
1043 
(50.1)
997 
(51.4)
1057 
(52.4)
1000 
(50.7)
979 
(46.4)
1125 
(48.2)
828 
(40.3)
10932
(49.0)
1.036 
(1.03, 
1.041)
< 0.001
> 10 to  
  ≤ 20 
466 
(36.0)
502 
(33.4)
452 
(32.8)
451 
(27.5)
688 
(34.8)
699 
(33.6)
614 
(31.7)
638 
(31.6)
654 
(33.2)
715 
(33.9)
779 
(33.4)
734 
(35.7)
7392
(33.2)
1.047 
(1.04, 
1.054)
< 0.001
> 20 to  
  ≤ 30
159 
(12.3)
196 
(13.0)
150 
(10.9)
129 
(7.9)
196 
(9.9)
203 
(9.8)
203 
(10.5)
194 
(9.6)
188 
(9.5)
254 
(12.0)
252 
(10.8)
285 
(13.9)
2409
(10.8)
1.052 
(1.04, 
1.065)
< 0.001
> 30 to  
  ≤ 40
44 
(3.4)
63 
(4.2)
64 
(4.7)
63 
(3.8)
69 
(3.5)
64 
(3.1)
70 
(3.6)
69 
(3.4)
61 
(3.1)
89 
(4.2)
80 
(3.4)
98 
(4.8)
834
(3.7)
1.048 
(1.027, 
1.068)
< 0.001
> 40
50 
(3.9)
45 
(3.0)
29 
(2.1)
37 
(2.3)
33 
(1.7)
71 
(3.4)
54 
(2.8)
61 
(3.0)
69 
(3.5)
74 
(3.5)
98 
(4.2)
109 
(5.3)
730
(3.3)
1.103 
(1.079, 
1.127)
< 0.001
BI-RADS category
1 or 2
6 
(0.5)
17 
(1.1)
10 
(0.7)
9 
(0.6)
8 
(0.4)
11 
(0.5)
21 
(1.1)
15 
(0.7)
9 
(0.5)
5 
(0.2)
4 
(0.2)
4 
(0.2)
119
(0.5)
0.951 
(0.902, 
1.002)
0.058
3
346 
(26.7)
310 
(20.6)
285 
(20.7)
237 
(14.5)
338 
(17.1)
360 
(17.3)
401 
(20.7)
347 
(17.2)
318 
(16.1)
306 
(14.5)
264 
(11.3)
156 
(7.6)
3668
(16.5)
0.979 
(0.970, 
0.988)
< 0.001
4a
608 
(47.0)
725 
(48.2)
711 
(51.6)
1004 
(61.3)
1211 
(61.3)
1254 
(60.3)
1100 
(56.8)
1229 
(60.9)
1238 
(62.8)
1274 
(60.4)
1472 
(63.1)
1222 
(59.5)
13048
(58.5)
1.062 
(1.056, 
1.067)
< 0.001
4b
42 
(3.3)
78
(5.2)
90 
(6.5)
100 
(6.1)
117 
(5.9)
124 
(6.0)
72 
(3.7)
79
(3.9)
84
(4.3)
116
(5.5)
141 
(6.0)
160 
(7.8)
1203
(5.4)
1.065 
(1.048, 
1.083)
< 0.001
4c
113 
(8.7)
130 
(8.6)
102 
(7.4)
93 
(5.7)
102 
(5.2)
130 
(6.3)
117 
(6.0)
99
(4.9)
97
(4.9)
132 
(6.3)
182 
(7.8)
223 
(10.9)
1520
(6.8)
1.054 
(1.038, 
1.069)
< 0.001
5
179 
(13.8)
244 
(16.2)
179
(13.0)
196 
(12.0)
199 
(10.1)
201 
(9.7)
227 
(11.7)
250 
(12.4)
226 
(11.5)
278 
(13.2)
271 
(11.6)
289 
(14.1)
2739
(12.3)
1.039 
(1.028, 
1.050)
< 0.001
Values are presented as numbers of core-needle biopsies with percentages in parenthesis. OR is defined as how many times number of 
biopsies increased each year. BI-RADS = Breast Imaging-Reporting and Data System
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increased while the proportion of benign lesions decreased 
over time (Fig. 2).
Unadjusted and Adjusted Time Trends in the Malignancy 
Rate
For the malignancy rate, the unadjusted results showed 
significantly increasing trends in rates of total malignancy 
(p < 0.001), DCIS (p < 0.001), and invasive cancer (p 
= 0.039). After adjusting for the BI-RADS category, the 
increasing trends in rates of total malignancy (p < 0.001) 
and DCIS (p < 0.003) remained significant, but the rate 
of invasive cancer did not show a statistically significant 
increasing trend (p = 0.215). Figure 3 shows the time trend 
line (by linear regression) in the rate of total malignancy 
based on the BI-RADS category. The increasing trends in 
the malignancy rate were statistically significant in BI-
RADS categories 4a (p < 0.001), 4b (p = 0.001), and 4c 
(p = 0.046) for DCIS, BI-RADS category 4b (p = 0.024) for 
invasive cancer, and BI-RADS categories 4a (p = 0.020), 4b 
(p < 0.001), and 4c (p = 0.002) for total malignancy (Table 4).
DISCUSSION
Our results show that in a large series (n = 22297) of 
US-guided CNBs for breast lesions, the overall number of 
both US scans and US-guided CNBs increased from 2005 
to 2016. The increase in the total number of US scans 
performed may partly contribute to the increase in the 
NY, USA), and a p value of less than 0.05 was considered 
statistically significant.
RESULTS
Time Trends in CNB Based on the Lesion Size, BI-RADS 
Category, and Pathology
Both the total number of US scans and US-guided CNBs 
increased significantly during the study period while 
the proportion of US-guided CNBs to the total number 
of US scans decreased 0.952 times per year (OR = 0.952 
per year, 95% confidence interval [CI]: 0.948, 0.956, p 
< 0.001) (Table 1). Table 2 shows distributions of US-
guided 14-gauge CNB based on the lesion size and BI-
RADS category. Table 3 shows the distribution of US-guided 
14-gauge CNB based on the pathologic results. Figure 1 
illustrates distributions US-guided 14-gauge CNB based on 
the lesion size, BI-RADS category, and pathologic results. 
With the Poisson regression analysis, we found statistically 
significant trends in all variables (p < 0.001, respectively), 
except for BI-RADS categories 1 and 2. BI-RADS category 3 
lesions showed a statistically significant decreasing trend of 
0.979 times per year (95% CI: 0.970, 0.988; p < 0.001). The 
number of BI-RADS category 1 or 2 lesions also decreased 
to 0.951 times per year without statistical significance 
(95% CI: 0.902, 1.002; p = 0.058), and the rest of the 
variables showed an increasing trend over time. Among all 
biopsied cases, the proportion of high-risk and DCIS lesions 
Table 3. Distribution of US-Guided 14-Gauge Core-Needle Biopsy According to Pathologic Results
Pathologic 
Results 
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total
OR
(95% CI)
P
Benign
941 
(72.7)
1063 
(70.7)
1013 
(73.6)
1250 
(76.3)
1513 
(76.6)
1575 
(75.7)
1468 
(75.8)
1497 
(74.2)
1467 
(74.4)
1469 
(69.6)
1619 
(69.4)
1320 
(64.3)
16195
(72.6)
1.035 
(1.032, 
1.038)
< 0.001
High risk
37
(2.9)
30
(2.0)
26
(1.9)
45
(2.8)
74
(3.8)
64
(3.1)
52
(2.7)
57 
(2.8)
81 
(4.1)
111 
(5.3)
111 
(4.8)
108 
(5.3)
796
(3.6)
1.129 
(1.112, 
1.146)
< 0.001
Total  
  malignancy
316 
(24.4)
411 
(27.3)
338 
(24.6)
344 
(21.0)
388 
(19.7)
441 
(21.2)
418 
(21.6)
465 
(23.0)
424 
(21.5)
531 
(25.2)
604 
(25.9)
626 
(30.5)
5306
(23.8)
1.058 
(1.05, 
1.067)
< 0.001
DCIS
35 
(2.7)
44 
(2.9)
33 
(2.4)
47 
(2.9)
49 
(2.5)
62 
(3.0)
57 
(2.9)
62 
(3.1)
69 
(3.5)
94 
(4.5)
101 
(4.3)
98
(4.8)
751
(3.4)
1.107 
(1.09, 
1.124)
< 0.001
Invasive  
  cancer
281 
(21.7)
367 
(24.4)
305 
(22.2)
297 
(18.1)
339 
(17.2)
379 
(18.2)
361 
(18.6)
403 
(20.0)
355 
(18.0)
437 
(20.7)
503 
(21.6)
528 
(25.7)
4555
(20.4)
1.051 
(1.044, 
1.057)
< 0.001
Values are presented as numbers of core-needle biopsies with percentages in parenthesis. OR is defined as how many times number of 
biopsies increased each year. DCIS = ductal carcinoma in situ
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number of biopsies; however, the proportion of US-guided 
CNBs among the total number of US scans decreased over 
time. One possible reason for this proportional decrease is 
revisions made to BI-RADS during the study period. The 5th 
edition of BI-RADS released in 2013 had several changes 
in the US section to include newer technology, such as 
elastography, and some additional descriptors in its lexicon 
(11, 12). There were several studies in which additional 
sonoelastography led to downgrading of BI-RADS 4a masses, 
potentially reducing the number of unnecessary biopsies 
(13-15). In our study, the decreasing rate of biopsies over 
time might be partly attributed to efforts made to reduce 
the number of unnecessary biopsies with various novel 
techniques, such as elastography. 
Our analysis revealed that only BI-RADS category 3 
lesions decreased significantly over time in terms of both 
the total number and percentage (26.7% in 2005 to 7.6% 
in 2016) among the total biopsied lesions. The total 
malignancy rate among BI-RADS category 3 lesions remained 
at approximately 1% throughout the study period. This 
observation is encouraging as otherwise there might have 
been more unnecessary patient cost and anxiety caused by 
biopsy because of the high rate of benign lesions in the 
biopsy results for BI-RADS category 3 lesions. One possible 
explanation for this may be the efforts to downgrade BI-
RADS category 3 lesions by radiologists at our institution. 
Since March 2010, we have trained our radiologists to 
downgrade certain lesions found using supplemental 
Fig. 1. Distribution of US-guided 14-gauge core-needle biopsies based on lesion size (A), BI-RADS category (B), and pathologic 
results (C) from 2005 to 2016. BI-RADS = Breast Imaging-Reporting and Data System, DCIS = ductal carcinoma in situ, US = ultrasonography
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CNB should be constant or increase in order to ensure 
that unnecessary biopsies were not performed. Among 
cases of total malignancy, the rate of DCIS showed an 
increasing trend during our study period. This observation 
can be attributed to the widespread use of screening 
mammography, which reveals clinically occult pre-invasive 
disease, and advances of other diagnostic imaging 
modalities, such as US and magnetic resonance imaging 
(17-19). In addition, improved resolution and technique 
have enabled visualization of microcalcifications on US, 
thus increasing the detection rate of DCIS using US-guided 
biopsy, which was formerly diagnosed using stereotactic-
guided biopsy (20-22).
When lesions were classified based on the BI-RADS 
category, the total malignancy rates of BI-RADS category 
4a, 4b, and 4c lesions showed slightly increasing trends 
screening US to BI-RADS category 2 in efforts to reduce the 
false-positive rate (16). In a previous study, the downgrade 
criteria reduced the BI-RADS category 3 rate from 28.3% 
to 12.6% without loss of cancer detection, and the biopsy 
rate also decreased significantly over 3 years. Despite using 
different inclusion criteria in the two studies, our results 
showed that the decrease in the BI-RADS category 3 rate 
was most prominent and persistent from 2011 to 2016, 
which fit the timeframe in which the downgrade criteria 
were first incorporated into the clinical practice at our 
institution.
The total malignancy rate in the results of US-guided CNB 
slightly increased over time with statistical significance, 
and this trend persisted after adjusting for the BI-RADS 
category. These results were consistent with our initial 
assumption that the malignancy rate in the results of 
Fig. 2. Line plot and trend lines for proportion of pathologic results. 
Linear lines (estimated by linear regression) show significant decrease in proportion of benign (A) lesions and significant increase in proportions 
of high-risk (B) and DCIS (C) lesions over time but no significant trend in proportion of invasive cancer (D) lesions. 
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over time. Because BI-RADS category 4 on US indicates 
a lesion suspected with malignancy for which biopsy is 
recommended, the aforementioned result may correlate 
with decreased false-positive results in the US findings 
of breast lesions. Our results showed that the malignancy 
rate based on the BI-RADS category generally matched the 
stratification of positive predictive values for each BI-RADS 
category during the past 12 years, with an exception in year 
2008 (92.9% in BI-RADS 5). BI-RADS suggests a positive 
predictive value of less than 2%, 3–10%, 11–50%, more 
than 95% for categories 3, 4a, 4b, 4c, and 5, respectively 
(11). 
In 2005, a community population-based trend study was 
performed on the frequency and malignancy rate of breast 
biopsies, similar to our study (23). However, many subjects 
of this past study underwent surgical biopsies, which are 
no longer recommended as the initial diagnostic approach 
(24). In addition, unlike our study, there was no BI-RADS 
classification for US lesions, which is now used in clinical 
practice. Thus, our study better reflects the latest clinical 
management approaches chosen for breast lesions compared 
with the previous study. Another recent study described 
time trends in minimally invasive breast biopsy for 9 years 
(25); however, this study primarily analyzed geographic/
ethnic variations in breast biopsy and did not assess 
malignancy rates relating to unnecessary biopsies and cost-
ineffectiveness in the clinical practice, while our study 
focused on the malignancy rate of breast biopsies.
Our study has a few limitations. First, this study was 
retrospectively conducted at a single tertiary hospital; 
therefore, its results cannot be generalized immediately 
to other populations. Further multicenter studies are 
required before our results can be applied to general clinical 
circumstances. Second, there was no standard diagnostic 
reference, such as surgical excision or follow-up data, to 
confirm the pathologic results of CNB. However, US-guided 
14-gauge CNB is a reliable diagnostic modality that allows 
accurate assessments (4, 6, 7). A previous study at our 
institution showed reliable sensitivity (95.4%) and no 
false-positive results for US-guided CNB from 2005 to 2012 
(8). Third, we did not classify US-guided CNB based on the 
indication of biopsy (e.g., screening or diagnostic clinical 
setting), which would potentially affect trends. 
In conclusion, we found an overall slightly increasing 
trend in the malignancy rate in the results of US-guided 
14-gauge CNB for breast lesions and an increase in the total 
number of biopsies performed from 2005 to 2016. This trend 
persisted after adjusting for the BI-RADS category. We could 
also observe the efforts made to avoid unnecessary biopsies 
during the 12-year study period with a large population at a 
single institution.
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